Danaher Corp said on Tuesday it would buy molecular diagnostics company Cepheid in a deal valued at $4 billion, including debt, to strengthen its diagnostics unit.
Danaher will pay Cepheid $53 per share in cash, a premium of 54 percent to its Friday close of $34.42, and the transaction is expected to close in the fourth quarter.
16:50 Goldman Sachs, Citigroup earnings confirm Trump effect on banks18
18:46 Lockheed Martin CEO says company 'close to deal' on bringing down F-35 program costs18
13:48 Wells Fargo Profit Falls 5.4% as Mortgage Revenue Declines25
13:21 Bank of America profits surge on cost cuts, trading gains25